Alembic Pharmaceuticals will participate in the 16th Annual Global Investor Conference, titled Trinity India 2026, hosted by B&K Securities in Mumbai on May 29, 2026. The company plans to engage with institutional investors through physical meetings held on a one-to-one basis and in group settings to discuss its performance and outlook. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company confirmed that no unpublished price sensitive information (UPSI) will be shared during these meetings. This assurance ensures compliance with regulatory standards regarding the dissemination of material non-public information.

The notification was addressed to BSE Limited and the National Stock Exchange of India Ltd to keep the information on record. G. Krishnan, the Chief Financial Officer of the company, signed the communication.

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for Levothyroxine Sodium Tablets USP in multiple strengths. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product, Synthroid Tablets, marketed by AbbVie, Inc.

USFDA Approval Details

The final approval covers Levothyroxine Sodium Tablets USP in strengths of 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Levothyroxine sodium is indicated as a replacement or adjunct therapy for various forms of hypothyroidism and thyroid cancer.

Market Opportunity

According to IQVIA data, Levothyroxine Sodium Tablets USP have an estimated market size of US$ 1,869 million for the twelve months ending March 2026. This approval allows Alembic Pharmaceuticals to commercialize a product with significant demand in the US market.

Alembic Pharmaceuticals now holds a cumulative total of 239 ANDA approvals from the USFDA, comprising 220 final approvals and 19 tentative approvals.